Bioventus Q3 net sales up 25.9% to $137.1M, but cuts full-year 2022 guidance sharply

Bioventus Inc.

2022-Q3 EPS reported -$2.07 revenue$386,283,000

Q3 net sales $137.1M (+25.9% YoY); net income $3.2M vs net loss $2.3M prior year.
Adjusted EBITDA $22.7M (+$1.3M YoY); Non-GAAP EPS $0.08, down from $0.19 prior year.
Full-year 2022 guidance lowered: net sales $527-532M, Adj. EBITDA $75-79M, Non-GAAP EPS $0.20-0.25.
Debt increased to $424.4M from $357.7M at Dec 2021; cash $34.4M.
CEO highlights recent CartiHeal acquisition to enter large cartilage replacement market.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Bioventus Inc. reported three and nine months ended October 1, 2022 results: revenue $137.1 million, net income $3.2 million, EPS $0.03.

Period: three and nine months ended October 1, 2022
Revenue: $137.1 million
Net income: $3.2 million
EPS: $0.03
Result: reported results

Exact text from the filing

in innovations for active healing, today reported financial results for the three and nine months ended October 1, 2022. Q3 Financial Summary & Recent Highlights: • Net Sales of $137.1 million, up $28.2 million, or 25.9%, year-over-year as reported (26.8% constant currency*) and 7.3% organically* (8.1% constant currency*) • Net Income of $3.2 million, compared to Net

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Bioventus Inc. reported twelve months ending December 31, 2022 results: revenue $527 million to $532 million, EPS $0.20 to $0.25. Guidance lowered.

Period: twelve months ending December 31, 2022
Revenue: $527 million to $532 million
EPS: $0.20 to $0.25
Guidance: lowered
Result: guidance update

Exact text from the filing

Updated Full Year 2022 Financial Guidance: For the twelve months ending December 31, 2022, the Company now expects: • Net sales of $527 million to $532 million, representing year-over-year growth of approximately 22% to 23%, representing an update to the prior guidance of $547.5 million to $562.5 million.

View on SEC.gov

Browse all earnings releases →

Bioventus Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-028761

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.